PRNewsWire
17 Jul 2026, 13:00 UTC · 7w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
IDEAYA's partner, Hengrui Pharma, targets the initiation of the first registrational trial for IDE849 (DLL3 TOP1 ADC) in SCLC and NECs by the end of 2026 in China and the US. — Moving a candidate into a registrational trial is a critical de-risking milestone that significantly increases the probability of commercialization and future revenue.
+0.60IDEAYA will present data updates from three darovasertib trials in uveal melanoma (OptimUM-01, OptimUM-02, and OptimUM-09) at the ESMO 2026 meeting. — Upcoming clinical data readouts for a lead candidate can cause significant short-term price volatility depending on the efficacy and safety results.
+0.40Hengrui Pharma will present long-term Phase 1 study results for IDE849 in relapsed small cell lung carcinoma and other neuroendocrine carcinomas at ESMO 2026. — Long-term Phase 1 data provides essential validation of the drug's durability and safety profile before entering pivotal trials.
+0.30Continue reading
5 related stories
Search tags
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
